Drugdocs | Praxbind

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Praxbind

Chemical Name	idarucizumab
Dosage Form	Injection (intravenous; 2.5 g/50 mL)
Drug Class	Monoclonal antibodies
System	Blood
Company	Boehringer Ingelheim
Approval Year	2015

Indication

For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects.

Last updated on 11/2/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Praxbind (idarucizumab) Prescribing Information	2018	Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

Document Title	Year	Source
Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature.	2019	Clinical Neurology and Neurosurgery
The reversal of bleeding caused by new oral anticoagulants (NOACs): A systematic review and meta-analysis.	2018	Clinical and Applied Thrombosis/Hemostasis
Idarucizumab in dabigatran-treated patients with acute ischemic stroke receiving alteplase: a systematic review of the available evidence.	2017	CNS Drugs
Efficacy and safety of the drugs used to reverse direct oral anticoagulants: a systematic review and meta-analysis.	2017	Transfusion

Document Title	Year	Source
European Stroke Organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage.	2019	European Stroke Journal
Management of bleeding and emergency invasive procedures in patients on dabigatran: Updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) - September 2016.	2018	Anaesthesia, Critical Care & Pain Medicine
Guideline for reversal of antithrombotics in intracranial hemorrhage.	2016	Neurocritical Care